UBS Group AG Reduces Position in AngioDynamics, Inc. $ANGO

UBS Group AG cut its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 33.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 730,078 shares of the medical instruments supplier’s stock after selling 372,410 shares during the period. UBS Group AG owned approximately 1.77% of AngioDynamics worth $9,374,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of ANGO. Millennium Management LLC boosted its position in shares of AngioDynamics by 28.1% during the third quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock valued at $20,030,000 after buying an additional 393,682 shares during the last quarter. Bastion Asset Management Inc. boosted its position in shares of AngioDynamics by 31.8% during the third quarter. Bastion Asset Management Inc. now owns 1,264,003 shares of the medical instruments supplier’s stock valued at $13,442,000 after buying an additional 304,960 shares during the last quarter. Divisadero Street Capital Management LP boosted its position in shares of AngioDynamics by 8.3% during the third quarter. Divisadero Street Capital Management LP now owns 3,678,125 shares of the medical instruments supplier’s stock valued at $41,085,000 after buying an additional 282,695 shares during the last quarter. Bank of America Corp DE boosted its position in shares of AngioDynamics by 729.4% during the second quarter. Bank of America Corp DE now owns 286,208 shares of the medical instruments supplier’s stock valued at $2,839,000 after buying an additional 251,702 shares during the last quarter. Finally, Moore Capital Management LP boosted its position in shares of AngioDynamics by 162.5% during the third quarter. Moore Capital Management LP now owns 237,964 shares of the medical instruments supplier’s stock valued at $2,658,000 after buying an additional 147,324 shares during the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.

AngioDynamics Stock Down 2.4%

NASDAQ ANGO opened at $10.77 on Friday. The stock’s 50-day moving average price is $10.75 and its 200-day moving average price is $11.43. AngioDynamics, Inc. has a 52 week low of $8.36 and a 52 week high of $13.99. The company has a market capitalization of $445.02 million, a P/E ratio of -14.36 and a beta of 0.37.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, April 2nd. The medical instruments supplier reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 4.66% and a negative net margin of 10.01%.The firm had revenue of $78.42 million for the quarter, compared to the consensus estimate of $76.77 million. Research analysts anticipate that AngioDynamics, Inc. will post -0.19 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Canaccord Genuity Group dropped their price objective on AngioDynamics from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research report on Monday, April 20th. Freedom Capital raised AngioDynamics to a “strong-buy” rating in a research report on Monday, April 6th. Finally, Zacks Research cut AngioDynamics from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $18.67.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.